Patients with estrogen receptor-positive (ER+) breast carcinoma often receive tamoxifen as an anti-estrogen therapy; however, a significant number still experience disease recurrence during treatment. The molecular mechanisms behind tamoxifen resistance are no... ...

请注册登录后继续浏览